Pharmaceutical companies are appealing a High Court judgement that upheld the National Institute for Health and Clinical Excellence's decision to restrict the use of anti-dementia medicines for NHS patients in the early stages of Alzheimer's disease.
Eisai and Pfizer, which are launching the appeal, say it is based on the need for greater transparency from NICE about the cost-effectiveness model used for these treatments.
Chris Hopson discusses the recently released 2019-20 planning guidance, which aims to help providers start recovering their financial performance
Essential insight into NHS matters in the North West of England, with a particular focus on the devolution project in Greater Manchester. Contact me in confidence here.
New funding allocations which favour areas of extreme deprivation will see some clinical commissioning groups receive cash growth of up to 15 per cent next year, with others receiving increases of less than 5 per cent.
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
Financial penalties are being lifted from high-profile standards including cancer and elective waiting times, so far without attracting much attention. How is this happening? And will it work, asks Rob Findlay
No comments yet